In the quest to control cancer we now face the challenge of translating our increasing insights into the cancer-immunity cycle into more effective immune therapies.
Last month’s American Society of Clinical Oncology (ASCO) meeting kicked off with a presentation from Professor Ruth Plummer, a medical oncologist from Newcastle in the UK who, in 2003, was
With the American Society of Clinical Oncology (ASCO) conference over for another year, Richard Staines presents a round-up of the most significant developments at this year’s event.
Kantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last day of ASCO 2019. MacroGenics' trial compared its margetuximab candida
